

Takeda Pharmaceutical Company Limited



The Global Fund / Sam Wolson

The challenge

Millions of lives are lost worldwide every year due to AIDS, tuberculosis and malaria, which are three of the world's most devastating infectious diseases. This constitutes a major obstacle to growth in developing countries. Africa suffers from a particularly severe shortage of health care providers, which hinders the provision of health care services to overcome such diseases.

The Global Fund partnership has saved 27 million lives since 2002 by investing in locally designed and implemented health programs, but efforts are still needed to increase the impact. Antenatal and postnatal care are suitable entry points for the critical expansion of disease prevention, screening and treatment. According to UNICEF, an estimated 86% of pregnant women globally access antenatal care with a skilled health worker at least once during their pregnancy (2010-2016).

However, the delivery of the recommended interventions during antenatal care, including screening, diagnosis and management of infectious diseases, remains below global targets.

Partnering with Takeda

Takeda has supported the Global Fund since 2010, making it the longest corporate partnership to date and an exemplary model of private sector engagement. Its financial support has helped strengthen the capacity of health workers in Kenya, Nigeria and Tanzania, and build resilient and sustainable health systems, a key strategic objective of the Global Fund.

Takeda's first pledge of JP¥ 1 billion (approximately US\$10 million) for 2010-2019 helped boost malaria prevention efforts in Tanzania with the distribution of mosquito nets; accelerated access to TB treatment in Kenya; and expanded HIV services and awareness in Nigeria.

In 2019, Takeda became the first private sector company to announce a financial commitment to the Global Fund's Sixth Replenishment, pledging an additional JP¥ 1 billion over five years. This investment is intended to support the improvement of maternal and child health by integrating quality HIV, tuberculosis and malaria services in antenatal and postnatal care in several priority countries in Africa.

Malaria prevention in Tanzania

Tanzania has led a robust effort to tackle AIDS, TB and malaria through prevention, care, treatment and support services.

Over 70 million mosquito nets have been distributed across the country with Global Fund support since 2002. Over the years, Tanzania has also benefited from Global Fund investment in sustainable and resilient systems for health. The funding has supported human resource capacity building through on-the-job training and deployment of health workers to remote areas; supply chain improvement; and strengthening routine data reporting.

Takeda's financial contribution to the Global Fund helped boost Tanzania's malaria prevention efforts between 2010 and 2019. It supported the government's National Insecticide-Treated Nets Implementation Plan for malaria prevention and strengthened health systems to distribute and promote the use of insecticide-treated nets.

Over 3 million insecticide-treated mosquito nets were distributed in the country in 2017 alone.

As a result of the malaria control interventions, Tanzania has nearly halved under-5 mortality. Yet more than 93% of Tanzanians are at risk of malaria. Malaria remains the leading cause of death in children under 5 and pregnant women, and continues to be one of the most important obstacles to economic development and foreign investment in Tanzania.

Christophe Weber

President & CEO, Takeda Pharmaceutical Company Limited

"Our commitment to better health and a brighter future extends beyond our work at the cutting edge of innovation to bold, long-term investments in disease prevention, capacity building, and access to health care in partnership with the global community. Supporting the Global Fund over the past 10 years has yielded results that are very important to us, and that is why we are proud to continue to partner with the Global Fund on the Takeda Initiative 2."

Peter Sands

Executive Director of the Global Fund

"We are very pleased to renew our partnership with Takeda and strengthen our collaboration in fighting HIV, TB and malaria. I hope Takeda's vote of confidence in the work we do will encourage other corporations in Asia and beyond to step up the fight to end the epidemics."

The Global Fund / Nicholas Peart



Pregnant woman receiving a mosquito net for malaria prevention at the Ikwiriri Health Center in Kibiti district, Tanzania.

STEP UP THE FIGHT

Ending the epidemics of HIV, TB and malaria by 2030 is within reach, but not yet firmly in our grasp. After years of remarkable progress, new threats such as stalled funding and growing drug resistance have pushed us off track. We now face a decisive moment. Do we step up the fight, or do we allow ourselves to slip back? The Global Fund's fundraising target for the next three-year cycle is at least US\$14 billion. The Global Fund is calling on the private sector to mobilize at least US\$1 billion. These funds will help save 16 million lives and cut the mortality rate from HIV, TB and malaria in half by 2023, while building stronger systems for health that will enable the achievement of universal health coverage. It is time to step up the fight.

About the Global Fund

The Global Fund is a partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. As an international organization, the Global Fund mobilizes and invests more than US\$4 billion a year to support programs run by local experts in more than 100 countries. In partnership with governments, civil society, technical agencies, the private sector and people affected by the diseases, we are challenging barriers and embracing innovation.

September 2019
theglobalfund.org